Emergence of drug resistance in human immunodeficiency virus type 1 infected patients from pune, India, at the end of 12 months of first line antiretroviral therapy initiation. - Wikidata - wikimedia - TriplyDB

Emergence of drug resistance in human immunodeficiency virus type 1 infected patients from pune, India, at the end of 12 months of first line antiretroviral therapy initiation.

Emergence of drug resistance in human immunodeficiency virus type 1 infected patients from pune, India, at the end of 12 months of first line antiretroviral therapy initiation.

http://www.wikidata.org/entity/Q37730759

about

Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western India Antiretroviral resistance following immunological monitoring in a resource-limited setting of western India: A cross-sectional study.

P2860

Q33595427-4177768E-6A02-468A-874C-9519686A7C09 Q40099629-852D3C0A-ED11-479F-B059-C3418528DEFC

P2860

Emergence of drug resistance in human immunodeficiency virus type 1 infected patients from pune, India, at the end of 12 months of first line antiretroviral therapy initiation.

http://www.wikidata.org/entity/Q37730759

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 April 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Emergence of drug resistance i ...... retroviral therapy initiation.

@en

Emergence of drug resistance i ...... retroviral therapy initiation.

@nl

type

label

Emergence of drug resistance i ...... retroviral therapy initiation.

@en

Emergence of drug resistance i ...... retroviral therapy initiation.

@nl

prefLabel

Emergence of drug resistance i ...... retroviral therapy initiation.

@en

Emergence of drug resistance i ...... retroviral therapy initiation.

@nl

P1433

Q37730759-1BF18B53-A122-405F-B979-394F4E9CBD04

P1476

Q37730759-62A59CEF-815B-4694-AF2B-CBD5BEDCB0CB

P2093

Q37730759-3BBD4DF2-E53A-4593-BD17-D700BBA7495B

Q37730759-54157C38-3F83-4EA4-864B-5629329475C8

Q37730759-56D8A829-95D9-45C2-A09B-350D856B63F1

Q37730759-5AD83C0C-3FF0-4534-94A4-F9D9F0D8339B

Q37730759-61D8844A-9869-4CA2-8E85-8F2EE190A705

Q37730759-73729BEB-BF92-407D-8D6A-BE222D33A254

P2860

Q37730759-0592EDEC-4FF0-42D9-96AB-735DE8DADD84

Q37730759-31C74820-9E66-4C1E-9EAB-06C17AE5D2AA

Q37730759-3977AE00-B300-4B90-9E2F-1F102BBDCE10

Q37730759-3A344931-A8B4-4B97-AFB3-BBA34534BDFC

Q37730759-3F86ECC0-9EED-47FA-9F3D-ABD8CFB1CE24

Q37730759-684269D4-F1CC-4C40-AB5C-0183121FC24B

Q37730759-77B755D7-97B5-40D6-ADB6-40EBD7126860

Q37730759-86C3DD18-AF58-4CF4-8084-AABB00CBA9E0

Q37730759-93139E0B-0543-4ECB-84EF-DCFF5ECDC793

Q37730759-9EA1315A-6D54-4C4B-8746-C2C033A3DFBF

P304

Q37730759-E7965BA4-5E0E-4465-9C46-0BAB51D9A3FE

P31

Q37730759-4626890F-C0C9-4EE7-A1CD-36596BE08BDF

P356

Q37730759-05E8F3D0-74CF-4477-A057-73D978416EB8

P478

Q37730759-F2C1B119-0939-4BDB-9AAB-7274E2F33114

P50

Q37730759-CFA0450B-84BC-4971-836D-E3D7855E17A6

P577

Q37730759-34DDAB34-5AE2-4EC0-93EF-6E2B67B1DD2D

P5875

Q37730759-B3351A7A-93A3-44F0-80A4-EF02F5B201C5

P698

Q37730759-4335301A-4657-40C0-A530-D6E58D893245

P921

Q37730759-3D9AF73D-4964-4593-8809-5348B688F0EA

Q37730759-B2B3EE70-3B72-4DA5-B712-DD7B7BA87214

P932

Q37730759-1550A862-0C1B-4438-8AA0-0612D914D355

P356

P1433

P1476

Emergence of drug resistance i ...... retroviral therapy initiation.

@en

P2093

Devidas N Chaturbhuj

http://www.w3.org/2001/XMLSchema#string

Nitin K Hingankar

http://www.w3.org/2001/XMLSchema#string

Rajesh T Patil

http://www.w3.org/2001/XMLSchema#string

Rajiv M Gupta

http://www.w3.org/2001/XMLSchema#string

Ramesh S Paranjape

http://www.w3.org/2001/XMLSchema#string

Srikanth P Tripathy

http://www.w3.org/2001/XMLSchema#string

P2860

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

One-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics: Mumbai, India.

Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study.

Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.

Initial virologic response and HIV drug resistance among HIV-infected individuals initiating first-line antiretroviral therapy at 2 clinics in Chennai and Mumbai, India

HIV-1 drug resistance mutations: an updated framework for the second decade of HAART

Surveillance of transmitted HIV type 1 drug resistance among HIV type 1-positive women attending an antenatal clinic in Kakinada, India.

Analysis of RT sequences of subtype C HIV-type 1 isolates from indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines.

Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.

World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.

P304

674906

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2014/674906

http://www.w3.org/2001/XMLSchema#string

P478

2014

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263816615

http://www.w3.org/2001/XMLSchema#string

P698

25006528

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

4003797

http://www.w3.org/2001/XMLSchema#string